Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 1449 - 1456 of 12026 results
$4.3 Million Or $1.27 Million? What’s The Point Of Scary Retirement Projection Numbers?
August 22, 2023| News
What Is A Major Advantage Of Separately Managed Accounts (SMAs)?
August 22, 2023| News
Health Law Diagnosed – CA Proposes Regs for Pre-Closing Review of Health Care Deals: What You Need to Know
August 21, 2023| Podcast| Viewpoint
FTC Proposed Settlement Requires Private Equity Firm to Divest Shares, Relinquish Potential Board Seat, and Other Expansive Remedies
August 21, 2023| Blog| Viewpoint
Can Enablement and Written Description Bars be Lower for Method-Of-Treatment Patent Claims?
August 21, 2023| Blog| Viewpoint
Distinguishing Patent Protection from Patient Safety – A Role for the FDA
August 21, 2023| Blog| Viewpoint
3 Reasons Why The Biopharma M&A Market Is Ready For Takeoff
August 21, 2023| News
Mintz Venture Watch — Volume 5: A Report on Deal Trends from Q1 and Q2 2023
August 21, 2023| Article| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
The Evolving Global Digital Infrastructure: Data Centers, AI, and the Next Wave of Connectivity
New York, NY
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|